[{"orgOrder":0,"company":"Scripta Therapeutics","sponsor":"Oxford Science Enterprises | Apollo Health Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Scripta Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Scripta Therapeutics \/ Oxford Science Enterprises | Apollo Health Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Scripta Therapeutics \/ Oxford Science Enterprises | Apollo Health Ventures"}]

Find Clinical Drug Pipeline Developments & Deals by Scripta Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AES
                          Not Confirmed
                          AES
                          Not Confirmed

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Study Phase : Discovery

                          Sponsor : Oxford Science Enterprises | Apollo Health Ventures

                          Deal Size : $12.0 million

                          Deal Type : Financing

                          Details : The financing will support the development of an undisclosed product for Alzheimer's disease.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          November 13, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : Discovery

                          Sponsor : Oxford Science Enterprises | Apollo Health Ventures

                          Deal Size : $12.0 million

                          Deal Type : Financing

                          blank